RET介导的自噬抑制作为急性髓系白血病可靶向的共依赖机制
研究通过功能基因组学方法鉴定RET为多种AML亚型的必需基因,发现AML细胞经ARTN/GFRA3和NRTN/GFRA2配体/共受体复合物激活RET信号,下游mTORC1介导的自噬抑制稳定突变FLT3等致白血病驱动蛋白;遗传或药理学抑制RET可损害FLT3依赖AML细胞生长并上调自噬、耗竭FLT3,小鼠模型和原代患者样本亦显示RET依赖,部分患者RET mRNA升高且RET与FLT3蛋白共表达。
要点
- RET在多种AML亚型中为必需基因,AML细胞经ARTN/GFRA3和NRTN/GFRA2激活RET信号。
- RET下游mTORC1抑制自噬并稳定突变FLT3等致白血病驱动蛋白。
- 遗传或药理学抑制RET可损害FLT3依赖AML细胞生长,伴自噬上调与FLT3耗竭。
核心结论
- RET-mTORC1信号通过抑制自噬促进AML,靶向RET或通过诱导自噬耗竭致白血病驱动蛋白在相关AML患者亚群中提供治疗机会。
研究设计与样本
- 采用功能基因组学方法鉴定AML必需基因,并在AML细胞系、小鼠AML模型和原代AML患者样本中验证。
主要发现
- RET被鉴定为多种AML亚型的必需基因,AML细胞经ARTN/GFRA3和NRTN/GFRA2配体/共受体复合物激活RET信号。
- RET下游通路分析发现mTORC1介导的自噬抑制及突变FLT3等致白血病驱动蛋白稳定是重要RET效应。
- 遗传或药理学抑制RET损害FLT3依赖AML细胞系生长,伴自噬上调与FLT3耗竭。
- 小鼠AML模型和原代AML患者样本中亦可见RET依赖。
- 转录组和免疫组化分析显示相当比例AML患者RET mRNA水平升高且RET与FLT3蛋白共表达。
临床怎么用
- 作者认为靶向RET或更广泛地通过诱导自噬耗竭致白血病驱动蛋白,在相关AML患者亚群中提供治疗机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many cases of AML are associated with mutational activation of receptor tyrosine kinases (RTKs) such as FLT3. However, RTK inhibitors have limited clinical efficacy as single agents, indicating that AML is driven by concomitant activation of different signaling molecules. We used a functional genomic approach to identify RET, encoding an RTK, as an essential gene in multiple subtypes of AML, and observed that AML cells show activation of RET signaling via ARTN/GFRA3 and NRTN/GFRA2 ligand/co-receptor complexes. Interrogation of downstream pathways identified mTORC1-mediated suppression of autophagy and subsequent stabilization of leukemogenic drivers such as mutant FLT3 as important RET effectors. Accordingly, genetic or pharmacologic RET inhibition impaired the growth of FLT3-dependent AML cell lines and was accompanied by upregulation of autophagy and FLT3 depletion. RET dependence was also evident in mouse models of AML and primary AML patient samples, and transcriptome and immunohistochemistry analyses identified elevated RET mRNA levels and co-expression of RET and FLT3 proteins in a substantial proportion of AML patients. Our results indicate that RET-mTORC1 signaling promotes AML through autophagy suppression, suggesting that targeting RET or, more broadly, depletion of leukemogenic drivers via autophagy induction provides a therapeutic opportunity in a relevant subset of AML patients.
引用
- Rudat S, Pfaus A, Cheng YY, et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018. PMID: 29654265. doi:10.1038/s41375-018-0102-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。